http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-098880-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_01ab668a971547b35eb36f8eb06e02d9 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0205 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P41-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01N1-0226 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4412 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-197 |
| filingDate | 2014-12-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-098880-A2 |
| titleOfInvention | PROTECTIVE SOLUTION TO PREVENT ISCHEMICAL DAMAGES IN ORGANS OR IN ISOLATED CELL SYSTEMS OR IN FABRIC COMPONENTS AFTER PERFUSION, OPERATION, TRANSPLANT OR CRIO-CONSERVATION AND SUBSEQUENT REPERFUSION |
| abstract | A protective solution to prevent ischemic damage in the organs, or in isolated cellular systems, or in tissue components after perfusion, operation, transplantation, or cryopreservation and subsequent reperfusion, which comprises an electrolyte selected from the group consisting of ions alkaline and alkaline earth ions, a buffer, a polyol and / or a saccharide, wherein said solution has an osmolarity of 290 mosm / L at 350 mosm / L, as well as a pH with a value of 6.8 to 7, 4 and comprises 3,4-dimethoxy-N-methylbenzohydroxamic acid and / or a salt thereof, said composition further comprising N-acetylhistidine as a buffer agent in combination with arginine, with an anionic aspartate content, in which acid 3, 4-dimethoxy-N-methylbenzohydroxamic and / or a salt thereof is comprised in an amount of up to 10 mmol / L, in which the N-acetylhistidine is comprised in a concentration of 30 mmol / L at 265 mmol / L, in which sodium is cont deliberately referred to as an electrolyte at a concentration of 10 mmol / L at 80 mmol / L, in which potassium is deliberately contained as an electrolyte at a concentration of 5 mmol / L at 25 mmol / L, in which magnesium is deliberately contained as an electrolyte at a concentration of 3.5 mmol / L at 27 mmol / L, in which calcium is deliberately contained as an electrolyte at a concentration of 0.005 mmol / L at 0.095 mmol / L, where aspartate it is contained at a concentration of up to 140 mmol / L, and wherein the a-ketoglutarate is contained at a concentration of 1 mmol / L at 9 mmol / L. Claim 2: Protective solution according to claim 1, characterized in that it comprises an addition of a 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid derivative, preferably of the respective methyl ester. Claim 3: Protective solution according to any one of the preceding claims, characterized in that it has a lysine cation content and / or lysine derivative, preferably lysine-containing dipeptides. Claim 5: Protective solution according to any one of claims 2 to 4, characterized in that the derivative of 6-hydroxy-2,5,7,8-tetramethyl-Ichroman-2-carboxylic acid, preferably as the methyl ester derivative, is comprised in a concentration of up to about 10 mmoI / L. |
| priorityDate | 2002-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.